US drugmaker Merck scraps £1bn London research centre and cuts 125 science jobs

US pharmaceutical company Merck has announced the cancellation of a £1 billion research center in London, resulting in the loss of 125 science jobs in the UK capital. This decision represents a significant setback for the country's vital life science sector, which the government has identified as a key economic asset. The move comes as industry groups warn that the UK is losing ground in terms of investment and research in this critical field. The previous administration had set a goal of transforming the UK into a global leader in science and technology by the end of the decade, but this latest development suggests that the country may be struggling to maintain its position in the life sciences industry. The decision by Merck to scrap the London research center highlights the challenges facing the UK's life science sector and the need for the government to address any underlying issues that may be deterring investment and innovation in this crucial area of the economy.